While these steps are mandatory before moving into clinics and re-evaluating the therapeutic efficacy of mongersen in IBD, additional experimentation is needed to further examine the contribution of Smad7 in the IBD-associated inflammatory response. This evidence concerns the gene SMAD7 and inflammatory bowel disease.